Cargando…

Comparative effectiveness of oral prostacyclin pathway drugs on hospitalization in patients with pulmonary hypertension in the United States: a retrospective database analysis

Two oral medications targeting the prostacyclin pathway are available to treat pulmonary arterial hypertension in the United States: oral treprostinil and selexipag. We compared real-world hospitalization in patients receiving these medications. A retrospective administrative claims study was conduc...

Descripción completa

Detalles Bibliográficos
Autores principales:	McConnell, John W., Tsang, Yuen, Pruett, Janis, III, William Drake
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7675886/ https://www.ncbi.nlm.nih.gov/pubmed/33240480 http://dx.doi.org/10.1177/2045894020911831

Ejemplares similares

Prostacyclin Use Among Patients with Pulmonary Arterial Hypertension in the United States: A Retrospective Analysis of a Large Health Care Claims Database
por: Burger, Charles D., et al.
Publicado: (2018)

Retrospective Database Analysis of Treatment Patterns Among Patients with Pulmonary Arterial Hypertension
por: Studer, Sean, et al.
Publicado: (2019)

Treatment patterns, healthcare resource utilization, and healthcare costs among patients with pulmonary arterial hypertension in a real-world US database
por: Studer, Sean, et al.
Publicado: (2018)

Burden of pulmonary hypertension in patients with portal hypertension in the United States: a retrospective database study
por: Sahay, Sandeep, et al.
Publicado: (2020)

Baseline history of patients using selexipag for pulmonary arterial hypertension
por: Highland, Kristin B., et al.
Publicado: (2019)

Use of prostacyclin in pulmonary hypertension
por: Vicente, R, et al.
Publicado: (1998)

Role of prostacyclin in pulmonary hypertension
por: Mitchell, Jane A., et al.
Publicado: (2014)

Transitions between infused and oral prostacyclin pathway agents in pulmonary arterial hypertension: key considerations
por: Sargent, Therese, et al.
Publicado: (2020)

Clinical and genetic associations with prostacyclin response in pulmonary arterial hypertension
por: Halliday, Stephen J., et al.
Publicado: (2018)

Recent advances in targeting the prostacyclin pathway in pulmonary arterial hypertension
por: Lang, Irene M., et al.
Publicado: (2015)

Medication Adherence and Healthcare Costs Among Patients with Pulmonary Arterial Hypertension Treated with Oral Prostacyclins: A Retrospective Cohort Study
por: Dean, Bonnie B., et al.
Publicado: (2020)

First-in-child use of the oral selective prostacyclin IP receptor agonist selexipag in pulmonary arterial hypertension
por: Geerdink, Lianne M., et al.
Publicado: (2017)

Correction to: Medication Adherence and Healthcare Costs Among Patients with Pulmonary Arterial Hypertension Treated with Oral Prostacyclins: A Retrospective Cohort Study
por: Dean, Bonnie B., et al.
Publicado: (2020)

Subdural hematomas in pulmonary arterial hypertension patients treated with prostacyclin analogs
por: Louis, Lam, et al.
Publicado: (2012)

Management of prostacyclin side effects in adult patients with pulmonary arterial hypertension
por: Kingman, Martha, et al.
Publicado: (2017)

Comparative Efficacy and Safety of Prostacyclin Analogs for Pulmonary Arterial Hypertension: A Network Meta-Analysis
por: Zhang, Huijun, et al.
Publicado: (2016)

Impact of additional selexipag on prostacyclin infusion analogs in patients with pulmonary arterial hypertension
por: Momoi, Mizuki, et al.
Publicado: (2022)

Combination Therapy in Pulmonary Arterial Hypertension—Targeting the Nitric Oxide and Prostacyclin Pathways
por: Mandras, Stacy, et al.
Publicado: (2021)

Hemodynamic assessment of transitioning from parenteral prostacyclin to selexipag in pediatric pulmonary hypertension
por: Colglazier, Elizabeth, et al.
Publicado: (2022)

Elicitation of health state utilities associated with the mode of administration of drugs acting on the prostacyclin pathway in pulmonary arterial hypertension
por: Davies, Evan W, et al.
Publicado: (2018)

A multicenter, retrospective study of patients with pulmonary arterial hypertension transitioned from parenteral prostacyclin therapy to inhaled iloprost
por: Channick, Richard N., et al.
Publicado: (2013)

Additional Use of Prostacyclin Analogs in Patients With Pulmonary Arterial Hypertension: A Meta-Analysis
por: Wang, Pengwei, et al.
Publicado: (2022)

New Tricks for an Old Drug: Prostacyclins and Right Ventricular Contractility in Pulmonary Arterial Hypertension
por: Wertheim, Bradley M.
Publicado: (2022)

Inhaled therapies targeting prostacyclin pathway in pulmonary hypertension due to COPD: systematic review
por: Alqarni, Abdullah A., et al.
Publicado: (2023)

The pulmonary and haematological toxicity of inhaled aerosolised prostacyclin
por: van Heerden, PV, et al.
Publicado: (1997)

Right ventricular function mirrors clinical improvement with use of prostacyclin analogues in pediatric pulmonary hypertension
por: Hopper, Rachel K., et al.
Publicado: (2018)

Resource utilization at the time of prostacyclin initiation in children in pulmonary arterial hypertension: a multicenter analysis
por: Hart, Stephen A., et al.
Publicado: (2018)

Adverse Events of Prostacyclin Mimetics in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis
por: Picken, Christina, et al.
Publicado: (2019)

The direct and indirect health care costs associated with pulmonary arterial hypertension among commercially insured patients in the United States
por: Ogbomo, Adesuwa, et al.
Publicado: (2022)

Saudi experience in the management of pulmonary arterial hypertension; the outcome of PAH therapy with the exclusion of chronic parenteral prostacyclin
por: Idrees, Majdy, et al.
Publicado: (2015)

Transition from parental prostacyclin to selexipag: a case series of five pulmonary arterial hypertension patients
por: Holthaus, Nathan, et al.
Publicado: (2019)

Reversal of Right Ventricular Hypertrophy and Dysfunction by Prostacyclin in a Rat Model of Severe Pulmonary Arterial Hypertension
por: Vanderpool, Rebecca R., et al.
Publicado: (2022)

Prognosis of pulmonary arterial hypertension patients with pericardial effusion before and after initiation of parenteral prostacyclin therapy
por: Abu‐Rmaileh, Muhammad, et al.
Publicado: (2023)

PROSTACYCLIN IN HEALTH AND DISEASE
Publicado: (1983)

Prostacyclin: An Inflammatory Paradox
por: Stitham, Jeremiah, et al.
Publicado: (2011)

Prostacyclin Synthesis and Prostacyclin Receptor Expression in the Porcine Myometrium: Prostacyclin Potential to Regulate Fatty Acid Transporters, Cytokines and Contractility-Related Factors
por: Blitek, Agnieszka, et al.
Publicado: (2022)

A prospective, randomized study of inhaled prostacyclin versus nitric oxide in patients with residual pulmonary hypertension after pulmonary endarterectomy
por: Abe, Shinichiro, et al.
Publicado: (2016)

Prostacyclin Analogues Inhibit Platelet Reactivity, Extracellular Vesicle Release and Thrombus Formation in Patients with Pulmonary Arterial Hypertension
por: Gąsecka, Aleksandra, et al.
Publicado: (2021)

Using Real World Evidence to Describe Pulmonary Arterial Hypertension Treatment Patterns, Healthcare Resource Utilization, and Costs Associated with PDE-5 Inhibitor Monotherapy
por: Ruiz, George, et al.
Publicado: (2018)

Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist Selexipag
por: Kaufmann, Priska, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_lh7v5gn5t6bjda0easl6hk9muv